Clinical Trial Update: Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing two rabeprazole formulations for gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Rabeprazole 20 mg Enteric-coated Tablets (rabeprazole)
• Rabeprazole 50 mg DDR Capsules (rabeprazole)

Snippet

Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Conditions: Gastroesophageal Reflux Disease | Phase 4 | Status: COMPLETED